MDM2 and prostate cancer: High USP2 levels resulted in the downregulation of several miRs, including MYC-targeting miR-34b/c, which resulted in the deubiquitination of MDM2 and elevated MYC levels with subsequent p53 inactivation in prostate cancer cells [142].